Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.
Patrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto et al.
✦ AI-curated · Sources linked
In 30 seconds
Brightline-1 was a randomized phase II/III trial comparing first-line brigimadlin with doxorubicin in patients with MDM2-amplified, locally advanced or metastatic dedifferentiated liposarcoma. In the phase III comparison, median progression-free survival was 8.4 months with brigimadlin and 7.2 months with doxorubicin (hazard ratio, 0.79; 95% confidence interval, 0.6-1.06; P = 0.096), so the primary endpoint was not met. Brigimadlin had a higher confirmed objective response rate, but its safety profile did not appear more manageable. Translational analyses showed TP53 pathway activation but identified no predictive efficacy biomarkers.
Key findings
- Median progression-free survival was 8.4 months with brigimadlin versus 7.2 months with doxorubicin; the primary endpoint was not met.
- Confirmed objective response rates were 22.3% with brigimadlin and 8.6% with doxorubicin.
- Grade ≥3 neutropenia and thrombocytopenia occurred in 36.7% and 27.9% of brigimadlin-treated patients, respectively.
- Brigimadlin activated the TP53 pathway, but translational analyses identified no biomarkers predictive of efficacy.
Why it matters
The trial provides a randomized comparison of an MDM2-p53 antagonist with standard first-line doxorubicin in advanced DDLPS. Although brigimadlin produced more confirmed responses, it did not significantly improve the primary progression-free survival endpoint, and its adverse-event profile was not judged more manageable. These results help frame the potential and limitations of targeting MDM2 in this disease.
What to keep in mind
The primary progression-free survival endpoint was not met, and the reported confidence interval for the hazard ratio includes 1.0.